US OptionsDetailed Quotes

ACIU241115C10000

Watchlist
  • 0.00
  • 0.000.00%
15min DelayClose Nov 15 09:30 ET
0.00High0.00Low
Intraday
  • 5D
  • Daily

No Data

News

Comments

    Trytosaveabit
    Trytosaveabit
    Nov 14 06:03
    Update
    $AC Immune (ACIU.US)$ Reuters· 2 mins ago
    AC Immune Reports Positive Interim Results From Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
    Jaguar8
    Jaguar8
    Nov 14 06:02
    NEWS
    $AC Immune (ACIU.US)$
    AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
    AC Immune (NASDAQ: ACIU) announced positive interim results from its Phase 2 VacSYn trial of ACI-7104.056, an active immunotherapy for early Parkinson's disease.
    The treatment showed significant efficacy, inducing anti-a-synuclein antibody levels 16-fold higherthan placebo after 3 immunizations, with a 100% patient response rate.
    The trial rep...
    amiable Hedgehog_758
    amiable Hedgehog_758
    Sep 17 06:34
    $AC Immune (ACIU.US)$
    AC Immune Reaches Key Milestone in Alzheimer's Immunotherapy, Receives CHF 24.6M
    Benzinga· 10 mins ago5mins
    AC Immune (ACIU.US)
    3.270
    3.530
    +2.83%
    +7.95%
    AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced that it will receive the second ReTain-related milestone payment (CHF 24.6 million) under its agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson co...
    Trytosaveabit
    Trytosaveabit
    Sep 17 06:09
    News
    $AC Immune (ACIU.US)$ Press Release: AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer's Disease
    Dow Jones· 7 mins ago
    AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer's Disease
    AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer's Disease
    1
    Jaguar8
    Jaguar8
    Sep 17 06:02
    NEWS
    $AC Immune (ACIU.US)$
    AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease
    AC Immune SA (NASDAQ: ACIU) has received a second milestone payment of CHF 24.6 million from Janssen Pharmaceuticals for the rapid prescreening rate in the Phase 2b ReTain trial of ACI-35.030 (JNJ-2056) for preclinical Alzheimer's disease. This brings the total milestone payments for this trial to CHF 40 million. The potentially regist...
Read more